Articles On Pharmaxis (ASX:PXS)

The ASX 200 Health Index (XHJ) is up by 0.57% at the time of writing, compared to the broader index which is up by 0.03%. The US FDA has cleared Pharmaxis (ASX:PXS)’s Investigational New Drug application (IND) for a trial of its lead drug,...

The US FDA has cleared Pharmaxis' (ASX:PXS) Investigational New Drug (IND) application for a trial of PXS‐5505 in patients with hepatocellular carcinoma.

“Pharmaxis is entering a potentially transformational period as it advances a portfolio of novel small molecule inhibitors of amine oxidases,” says analyst.

Clinical stage drug development company Pharmaxis (ASX:PXS) has commenced dosing in the phase 2 clinical trial studying its investigative PXS-5505 in patients with the bone marrow cancer myelofibrosis.

Bone marrow cancer affects one in 100,000 people, but Pharmaxis’ lead asset could one day help treat patients with this condition.

The ASX 200 was unable to break free from its recent shackles, edging lower by 0.11% in the Wednesday session. But as a measure of a little more risk-on sentiment creeping back into markets, the microcap Emerging Markets index comfortably o...

“We are very pleased to have completed the dose-escalation phase of this study with such clear and positive findings,” Pharmaxis CEO Gary Phillips said.

The ASX 200 health stocks index (XHJ) is falling by 0.55% at the time of writing, compared to the broader ASX 200 index which fell by 0.50%. Fibrotic and inflammatory diseases-focused biotech, Pharmaxis (ASX:PXS), has just announced further...

Pharmaxis (ASX:PXS) has announced further positive results of data analysis from a phase 1c clinical trial (MF-101) studying its drug PXS-5505 in patients with bone marrow cancer myelofibrosis for 28 days at three dosage levels. ...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Topical treatment safe and well tolerated in study of healthy volunteers Full inhibition of lysyl oxidase enzymes achieved in skin with minimal systemic exposure Collaboration with research team led by Professor Fiona Wood AM planning fo...

“We will be investigating the safety of 3 months’ treatment with PXS‐6302, and exploring if 3 months’ treatment with PXS‐6302, at a dose that we now know will significantly inhibit an enzyme implicated in scar formation, can make a differen...

Top of the ASX health stocks today is Creso Pharma (ASX:CPH), which rose more than 10% after announcing plans to pursue a NASDAQ and ASX dual listing. The news follows a mutual termination of its proposed merger with Red Light Holland Corp....

Pharmaxis (ASX:PXS) has announced that its novel topical drug treatment for scarring has delivered positive phase one clinical trial results and will now advance to the next stage of development in patients.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Pharmaxis will receive an upfront US$250,000 payment for the 12‐month option and a further US$2.5 million if Aptar decides to exercise the option. In doing so, it will also pay Pharmaxis industry standard royalties on income received for Or...

Highlights AVITA Medical disclosed that the US Food and Drug Administration (FDA) has authorised its request to amend the RECELL® System pivotal trial. Pharmaxis has granted Aptar Pharma an exclusive 12-month option for developing and...

Global markets stay cool US stocks edged higher overnight to post their fifth straight day of gains, as attention centred around geo-political concerns following the US withdrawal from Afghanistan. The Dow Jones rose by 0.31%, and the S&am...

Summary  Latitude Group Holdings has cracked a deal for fintech Symple to accelerate business growth. Telstra Health has signed a pact to acquire MedicalDirector to support its vision of becoming a leading partner to the healthcare sec...

DATA PRESENTED FROM COLLABORATION OF PHARMAXIS AND UNIVERSITY OF ROCHESTER MEDICAL CENTER AT US SCIENTIFIC MEETING COMBINATION OF PXS-5505 AND STANDARD OF CARE DEMONSTRATES A NOVEL THERAPEUTIC STRATEGY FOR LIVER CANCER SYDNEY, Aug. 5, 2021...

The S&P/ASX200 closed up Thursday, gaining 7.90 points or 0.11% to 7,511.10 and setting a new 100-day high. The top performing stocks in this index were NIB Holdings Limited (ASX:NHF)  Nuix Limited (ASX:NXL), up 3.05% and 2.75% respecti...

Summary Benchmark index, the ASX200, rose 0.1% to hit a fresh closing high of 7,511. Eight of the 11 sectors ended in green, while consumer discretionary and A-REIT gained the most. Health insurance firm NIB Holdings topped the gainer...

Summary Emyria has signed a deal with the University of Western Australia (UWA) to develop a novel psychedelics pipeline. Pharmaxis’ anticancer drug PXS-5505 shows positive results in the pre-clinical liver cancer model. Immutep updat...

ASX 200 health stocks index (XHJ) rose by 0.23% this morning, compared to the broader index which rose by 0.11%. Micro cap medical device company dorsaVi (ASX:DVL) took the limelight this morning, jumping by 12% after saying that it has ext...

A research team at the University of Rochester Medical Center in New York State has been investigating the role of lysyl oxidase enzymes in liver cancer and whether PXS-5505 can improve the efficacy of current chemotherapy drugs by inhibiti...

Pharmaxis (ASX:PXS) has announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma.

Wall Street mixed on Fed’s statement US stock markets were mixed overnight, after the US Fed Vice Chair said he anticipates rates to increase by 2023. “Given this outlook and so long as inflation expectations remain well anchored at the 2%...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Summary REA Group (ASX:REA) completes transaction with PropertyGuru BNK Banking (ASX:BBC) announces alliance with Goldman Sachs for A$500m Securitisation Warehouse Westpac (ASX:WBC) to kick-off jab program for Western Sydney The S...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week Healthcare fi...

It wasn’t a happy start to the new financial year for Australia’s bourse, which lost nearly two thirds of one per cent today. Likewise, the ASX200, which rose 22% in FY21, closed down 0.65% to 7,266. Meanwhile, the ASX Emerging Companies In...

Under the agreement, BTC Health will acquire marketing authorisations for both products in Australia, New Zealand, Singapore, Malaysia and Hong Kong.

Australian company Pharmaxis (ASX:PXS) has announced results of data analysis from the first of three stages in its phase one trial studying a potential new treatment for the bone marrow cancer myelofibrosis and announced the sale o...

The second dose cohort of the clinical trial is fully recruited and dosing of all patients has commenced at participating sites in Australian and South Korean hospitals.

Summary The OVT share price has risen by 50% to AU$0.003 in today’s session, clocking a volume of over 30.7 million shares. Amid a trading update and FY21 guidance update, the GTN share price surged to AU$0.41, an increase of 28.1%. P...

The company’s PXS-5505 multinational trial in Myelofibrosis has been cleared by the safety committee to advance to the second stage of Dose escalation study.

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

A drug candidate discovered by the Australian company Pharmaxis (ASX:PXS) will be the focus of a new trial aimed at studying its potential as a treatment for an aggressive and deadly form of brain cancer.

Summary Pharmaxis Ltd and Charlie Teo Foundation have identified a new drug that shows promise in tackling a deadly form of brain cancer. Pharmaxis’ PXS-5505 will be a part of preclinical testing to assess its efficacy for glioblastoma...

PXS-5505 will enter pre-clinical efficacy testing for glioblastoma, the most common form of brain cancer with an average survival of only 15 months from diagnosis.